Design, synthesis, biological evaluation and in silico studies of 2-anilino- 4-(benzimidazol- 1-yl)pyrimidine scaffold as antitumor agents.

ABSTRACT: In an attempt to rationalize the search for new potential Chemotherapeutic agents, a new series of 2-anilinobenzimidazol derivatives with CDK activity have been synthesized. The newly synthesized compounds have been assessed for their cytotoxic effects and CDK activity. These presented compounds showed strong inhibition of cell proliferation in various solid cancer cell lines, suggesting a promising approach for treating malignant tumors. Compounds 4 g, 4j, 4 m, and 4q displayed remarkably strong anticancer potencies against HepG2 cells, with IC₅₀ of 7.59, 8.54, 3.56 and 5.88 µM, respectively, compared to the positive control, DOX (IC₅₀ = 4.50 µM). while compound 4 m, and 4q had the highest anticancer activity against HeLa cells, with an IC₅₀ of 6.39 and 9.

SUBMITTER: Al-Rasheed LS 

PROVIDER: S-EPMC12102023 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature